Comera Gets Approval, with Over 98% Redemptions

by | May 13, 2022

Comera gets approved, albeit with whopping 98.4% redemptions. A $60M IPO for PNACU. And the rest of the day’s news in SPACs.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

SPAC IPO: Prime Number Acquisition I Corp. (PNACU)

Prime Number Acquisition I Corp. (PNACU) prices $60M IPO. $10.20 cash in trust. Unit = share + 1/2 warrant + 1/8 Right. The SPAC, whose target focus is tech/finance, is led by CEO and Chairman Dongfeng Wang, venture partner at China’s LongLing Capital and the Chief Strategy Officer of Taoping (TAOP). CFO and Director David Friedman is the current CFO of optical sensor company Oyla. 

OTR Approves Merger with Comera Life Sciences; High redemptions

Potential squeeze alert: OTR Acquisition Corp. (OTRA) approved its merger with biotech Comera Life Sciences (CMRA). High redemptions– 10.3M shares redeemed (98.4%). That leaves ~168,000 tradable shares. No PIPE. Risk that the deal may not close given the low capital and high redemptions.

Elsewhere in SPACs

  • Kingswood Acquisition Corp. (KWAC) announces an LOI with Wentworth Management Services, a platform of RIAs/broker dealers. The news comes just ahead of extension vote Wednesday. KWAC seeks a 6 month extension.
  • Lionheart Acquisition Corporation II (LCAP) announced a new $1B committed equity facility with Cantor to buy 3.5M of any redeemed shares “at a per share purchase price at or below the redemption price for the shares.” The FPA would trigger before the closing of LCAP’s proposed business combination with MSP Recovery.
  • Better World Acquisition Corp. (BWAC) adds $500k (~7c / share) to trust, bringing NAV to ~$10.37. Shareholders redeemed 5.6M shares at approximately $10.30 / share.
Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

Daily SPAC Update – April 5, 2024

KYCH DeSPACs to ZOOZ. PLTN Deal Vote Set. HUDA Ext Vote Set. TLGY Delays to April 16. NSTD / NSTC Distributions Announced. IXAQ Deal Deck.

Daily SPAC Update – April 3, 2024

CITE Extension Vote. GMFI Extends. GODN Reduces Extension Fees. LGVC Deal Approved. ACAB & SEDA Deal Decks. CCTS + Tembo E-LV Deal Agreement.

Daily SPAC Update – April 2, 2024

MBTC / Cognos Deal Terminates. ACBA Extension Vote. ARRW Deal Approved. VHAQ, DSAQ Extensions Approved. SEDA Investor Deck. CITE Redemption Update.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.